436 related articles for article (PubMed ID: 14586718)
1. Effects of the angiotensin II type 1 receptor antagonist candesartan, compared with angiotensin-converting enzyme inhibitors, on the urinary excretion of albumin and type IV collagen in patients with diabetic nephropathy.
Sato A; Tabata M; Hayashi K; Saruta T
Clin Exp Nephrol; 2003 Sep; 7(3):215-20. PubMed ID: 14586718
[TBL] [Abstract][Full Text] [Related]
2. Combination of half doses of angiotensin type 1 receptor antagonist and angiotensin-converting enzyme inhibitor in diabetic nephropathy.
Fujisawa T; Ikegami H; Ono M; Nishino M; Noso S; Kawabata Y; Ogihara T
Am J Hypertens; 2005 Jan; 18(1):13-7. PubMed ID: 15691611
[TBL] [Abstract][Full Text] [Related]
3. Effects of candesartan, an angiotensin II type 1 receptor blocker, on diabetic nephropathy in KK/Ta mice.
Liao J; Kobayashi M; Kanamuru Y; Nakamura S; Makita Y; Funabiki K; Horikoshi S; Tomino Y
J Nephrol; 2003; 16(6):841-9. PubMed ID: 14736011
[TBL] [Abstract][Full Text] [Related]
4. Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-beta in type 2 diabetic patients with advanced kidney disease.
Song JH; Cha SH; Lee HJ; Lee SW; Park GH; Lee SW; Kim MJ
Nephrol Dial Transplant; 2006 Mar; 21(3):683-9. PubMed ID: 16330466
[TBL] [Abstract][Full Text] [Related]
5. Renal protection and angiotensin converting enzyme inhibition in microalbuminuric type I and type II diabetic patients.
Cooper ME
J Hypertens Suppl; 1996 Dec; 14(6):S11-4. PubMed ID: 9023709
[TBL] [Abstract][Full Text] [Related]
6. [Angiotensin II type-1 receptor antagonists and diabetes mellitus].
Schnack C; Schernthaner G
Wien Med Wochenschr; 2001; 151(7-8):165-8. PubMed ID: 11450165
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
8. Add-on angiotensin receptor blocker in patients who have proteinuric chronic kidney diseases and are treated with angiotensin-converting enzyme inhibitors.
Kanno Y; Takenaka T; Nakamura T; Suzuki H
Clin J Am Soc Nephrol; 2006 Jul; 1(4):730-7. PubMed ID: 17699280
[TBL] [Abstract][Full Text] [Related]
9. Effect of combination therapy of angiotensin-converting enzyme inhibitor plus calcium channel blocker on urinary albumin excretion in hypertensive microalbuminuric patients with type II diabetes.
Shigihara T; Sato A; Hayashi K; Saruta T
Hypertens Res; 2000 May; 23(3):219-26. PubMed ID: 10821130
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin II type 1 receptor blockers reduce urinary oxidative stress markers in hypertensive diabetic nephropathy.
Ogawa S; Mori T; Nako K; Kato T; Takeuchi K; Ito S
Hypertension; 2006 Apr; 47(4):699-705. PubMed ID: 16505207
[TBL] [Abstract][Full Text] [Related]
11. Effects of monotherapy of temocapril or candesartan with dose increments or combination therapy with both drugs on the suppression of diabetic nephropathy.
Ogawa S; Takeuchi K; Mori T; Nako K; Tsubono Y; Ito S
Hypertens Res; 2007 Apr; 30(4):325-34. PubMed ID: 17541211
[TBL] [Abstract][Full Text] [Related]
12. The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-beta excretion in 2 groups of patients with IgA and diabetic nephropathy.
Song JH; Lee SW; Suh JH; Kim ES; Hong SB; Kim KA; Kim MJ
Clin Nephrol; 2003 Nov; 60(5):318-26. PubMed ID: 14640237
[TBL] [Abstract][Full Text] [Related]
13. Possible role of VEGF in the progression of kidney disease in streptozotocin (STZ)-induced diabetic rats: effects of an ACE inhibitor and an angiotensin II receptor antagonist.
Kakizawa H; Itoh Y; Imamura S; Matsumoto T; Ishiwata Y; Ono Y; Yamamoto K; Kato T; Hayakawa N; Oda N; Goto Y; Goto Y; Nagasaka A; Senda T; Itoh M
Horm Metab Res; 2004 Jul; 36(7):458-64. PubMed ID: 15305228
[TBL] [Abstract][Full Text] [Related]
14. [ACE inhibitors and early diabetic nephropathy].
Bangstad HJ; Hartmann A; Berg TJ; Hanssen KF
Tidsskr Nor Laegeforen; 1995 Oct; 115(24):3039-41. PubMed ID: 7570536
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin II receptor blocker and long-acting calcium channel blocker combination therapy decreases urinary albumin excretion while maintaining glomerular filtration rate.
Nakagawa N; Fujino T; Kabara M; Matsuki M; Chinda J; Kikuchi K; Hasebe N;
Hypertens Res; 2011 Oct; 34(10):1121-6. PubMed ID: 21796123
[TBL] [Abstract][Full Text] [Related]
16. Low-dose candesartan cilexetil prevents early kidney damage in type 2 diabetic patients with mildly elevated blood pressure.
Murayama S; Hirano T; Sakaue T; Okada K; Ikejiri R; Adachi M
Hypertens Res; 2003 Jun; 26(6):453-8. PubMed ID: 12862201
[TBL] [Abstract][Full Text] [Related]
17. Comparative effect of lisinopril and lacidipine on urinary albumin excretion in patients with type 11 diabetic nephropathy.
Salako BL; Finomo FO; Kadiri S; Arije A; Olatosin AO
Afr J Med Med Sci; 2002 Mar; 31(1):53-7. PubMed ID: 12518931
[TBL] [Abstract][Full Text] [Related]
18. Microalbuminuria reduction with telmisartan in normotensive and hypertensive Japanese patients with type 2 diabetes: a post-hoc analysis of The Incipient to Overt: Angiotensin II Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) study.
Makino H; Haneda M; Babazono T; Moriya T; Ito S; Iwamoto Y; Kawamori R; Takeuchi M; Katayama S;
Hypertens Res; 2008 Apr; 31(4):657-64. PubMed ID: 18633177
[TBL] [Abstract][Full Text] [Related]
19. Is the reno-protective effect of valsartan dose dependent? A comparative study of 80 and 160 mg day(-1).
Saikawa T; Sasaki J; Biro S; Kono S; Otonari T; Ikeda Y;
Hypertens Res; 2010 Sep; 33(9):886-91. PubMed ID: 20555331
[TBL] [Abstract][Full Text] [Related]
20. Effect of tranilast in early-stage diabetic nephropathy.
Soma J; Sato K; Saito H; Tsuchiya Y
Nephrol Dial Transplant; 2006 Oct; 21(10):2795-9. PubMed ID: 16820373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
